Waiting for biomarker testing results or having inadequate patient samples delays treatment for patients with non-small cell lung cancer (NSCLC). To ensure the right patients receive the right therapy at the right time, the turnaround time and accuracy of biomarker testing are key.
ASCP is committed to ensuring you have the resources, tools, and education you need to optimize the diagnosis, testing, and management of patients with NSCLC and ensure continuous quality improvement.
Best Practices from Experts and the Laboratory Community
View videoconference recordings and community-contributed examples of sample workflows and QI plans/processes. If you have sample workflows or QI plans/processes you would like to contribute, please send them to grants@ascp.org for consideration.
Access an action plan template to help you improve NSCLC biomarker testing processes and procedures, discuss best practices with peers in the ASCP NSCLC Biomarker Testing Facebook group, and share your input on biomarker testing challenges.
Access an extensive list of additional NSCLC resources covering topics including biomarker testing, preanalytic indicators, immunohistochemistry, next generation sequencing, liquid biopsy, targeted therapies, quality, reporting, and billing/reimbursement.
Educational activities funded through commercial support by Genentech and independent educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Pfizer, Inc.
This resource page was initially developed in collaboration with the Association of Community Cancer Centers (funded by an independent educational grant from Pfizer, Inc.), and further expanded upon through a commercial sponsorship from Genentech.
Connect today with your local Genentech biomarker testing specialist at: biomarkertesting.com/contact. To learn more about Genentech, please visit gene.com.
ASCP does not share identifying information from the action plans with its sponsors.
